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When injected intravenously into immunized animals, proteins and other macro- 
molecular antigens form complexes with their corresponding antibodies (2, 3), and the 
resulting antigen-antibody complexes are rapidly removed from  the circulation and 
deposited  in  various tissue sites  (4). When injected into  immunized animals, low 
molecular weight antigens or haptens are also thought to form complexes with their 
corresponding antibodies (5), but little is known about the fate of these presumed com- 
plexes. 
We have previously reported that the intravenous administration of a  hapten, di- 
goxin, into rabbits whose sera contained digoxin-specific  antibodies resulted in a prompt 
decrease in antidigoxin antibody titer which persisted for at least 1 wk (5). It was con- 
sidered likely that the fall in antibody titer reflected the formation of digoxin-antibody 
complexes, but no evidence in support of this hypothesis was obtained and no infor- 
mation was available to determine whether such complexes, if present, persisted in the 
circulation of the rabbit for prolonged periods or were rapidly cleared from the circu- 
ation in the manner in which protein-antibody complexes are cleared. 
We  now  present  evidence  that,  when  injected  into  immunized  animals,  a 
specific hapten, namely digoxin, indeed forms complexes with its corresponding 
antibodies and that  these complexes persist in the circulation for longer than 
1 yr after a  single intravenous injection of that hapten. 
Materials and Methods 
Reagents.--BSA 1  was obtained as Fraction V from Pentex Biochemical, Kankakee, Ill. Non- 
radioactive digoxin  was  supplied in crystalline form and in a  40%  propylene glycol-10% 
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HL-05741, and by grants-in-aid from  the New  York Heart Association  and  the  American 
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ethanol solution (0.25 mg/ml) through the courtesy of Dr. Stanley T. Bloomfield, Burroughs 
WeUcome & Co., Inc., Research Triangle Park, N.C. Two lots of randomly labeled digoxin-aH 
were employed in this study: one lot (R907,  144/zCi/mg in  95%  ethanol,  supplied  by Dr. 
Bloomfield) was used in all animal studies; while the other lot (185-165,  15.3 mCi/mg in 90% 
ethanol, 10% benzene; New England Nuclear Corp., Boston, Mass.) was used in digoxin-bind- 
ing  antibody  determinations.  3-0-Succinyl  digoxigenin  tyrosineA2~I  was  obtained  in  1% 
acetic acid in methanol from Schwarz/Mann Laboratories, Orangeburg,  N.Y.  125I (carrier- 
free) and lslI (35-50 mCihzg) were obtained as NaI in NaOH from the Cambridge Nuclear 
Corp., Billerica, Mass. All other reagents were commercial products of the highest degree of 
purity available. 
Immunological.--Synthetic  BSA-digoxin  (BSA-Dig)  conjugates  were  prepared  by  the 
periodate oxidation method (6, 7) as described in detail elsewhere (8).  White New Zealand 
rabbits were immunized with BSA or with a BSA-Dig conjugate in complete Freund's adju- 
vant mixture, as previously described (5). The duration of immunization and the number of 
antigen injections are listed in Table I. The presence of digoxin-binding antibodies was de- 
termined in serum obtained during the 24 h period prior to the intravenous administration of 
digoxin, by the dextran-coated characoal method (9, 10) as follows: to 1 ml portions of buffered 
albumin (5) were added 50 #1 of various dilutions of test serum followed by 50 #1 of digoxin-aH 
(30 ng/ml; 0.5 #Ci/ml). 10 min later, 0.25 ml of dextran T-70-coated charcoal (2% dextran, 
20% charcoal in Tris-buffered saline) was added. The separation and counting of protein-bound 
digoxin-SH were carried  out as  previously described  (5).  Digoxin-binding antibody  titers, 
which are functions of both antibody affinity and concentration, are expressed as the dilutions 
of antiserum (calculated by extrapolation and rounded off to the nearest unit divisible by 100), 
50 #1 of which was capable of binding 50% of the added digoxin-SH. 
Measurement of Complement Levels.--Serum complement levels were determined using the 
method of Kent et ai. (11). 
Rabbit "t-Globulin and Antidigoxin Antibody Purification and Radioiodination.--~-Globnlin 
from the serum of nonimmunized rabbits was purified by DEAE-cellulose chromatography 
(12), as previously described (6, 13). Antidigoxin antibody was purified from rabbit antidigoxin 
serum by the method of Curd et al. (14). Both preparations contained no detectable proteins 
TABLE I 
Summary of Immunization Data and Antibody Titers in Rabbits Studied 
Duration of  No. of antigen  Digoxin-binding  Weight  Rabbit no.  Immunizing  antigen  immunization  injections*  antibody titer~ 
wks  kg 
DC-20  BSA-Dig  33  13  1 : 1,600  3.93 
DC-23  BSA-Dig  33  12  1:600  4.00 
DC-24  BSA-Dig  32  12  1:800  4.29 
DC-25  B SA-Dig  28  11  1 : 800  3.83 
DC-26  BSA-Dig  28  11  1 : 2,400  3.65 
BSA-20  BSA  23  i0  0§  5.93 
BSA-26  BSA  58  20  0§  4.60 
BSA-33  BSA  72  21  0§  4.58 
BSA-37  BSA  72  21  0§  4.72 
* No further antigen injections were given after the single intravenous dose of digoxio-SH 
was administered. 
:~ See Materials and Methods for definition of digoxin-binding antibody titer. 
§ No detectable binding at a dilution of 1:20. 280  PERSISTENCE  OF  HAPTEN-ANTIBODY  COMPLEXES 
other than 3,-globulin as determined by cellulose acetate electrophoresis and immunoelectro- 
phoresis. The rabbit qt-globulin was radioiodinated with 121I and the antidigoxin antibody was 
radioiodinated with 1251 by the chloramine T method (15). The antidigoxin antibody retained 
its capacity to bind digoxin as determined by its capacity to bind 3-0-succinyl digoxigenin 
tyrosine-t2~I before and after purification and radioiodination. Radioiodinated "y-globulin and 
antidigoxin antibody were diluted in 0.15 M  phosphate-buffered saline solution, pH 7.4 (16), 
and centrifuged at 40,000 rpm for 90 min (Spinco model L-2 ultracentrifuge, Spinco Division, 
Beckman Instrument Co., Palo Alto, Calif.) to remove aggregated material (17), prior to use 
in  animal experiments. 
Metabolic Studies.-- 
Digoxin: Digoxin-aH for injection was prepared as follows: to 1 ml of digoxin-3H (lot R907, 
I mg/ml in 95% ethanol) were added 4 ml of nonradioactive digoxin solution (0.25 mg/ml) and 
20 ml 0.85% NaC1; 1 ml of the resulting solution contained 0.08 mg digoxin and 5.76/~Ci. 
Unanesthetized rabbits whose weights ranged between 2.58 and 5.93  kg were given 5 m] 
of this digoxin solution per kilogram of body weight (0.4 mg digoxin per kilogram). Following 
the administration of digoxin the rabbits were placed in metabolic cages and fed a regular diet. 
Serum samples were obtained at 12 and 24 h and daily thereafter up to 10 days. Rabbits whose 
serum contained digoxin-speeific antibodies were bled daffy for 4 additional days and then bled 
every 3 days for 2 additional weeks, weekly for 1 mo, and then every 2 wk until the animals 
died or were sacrificed. Urine samples were collected daily for the first 10 days in all animals 
studied. The total volume of each sample was determined, following which a 10 ml portionwas 
removed and frozen for subsequent analysis. Stool samples were also collected daily for 10 
days. The daily weight was recorded and the specimens stored at 4°C until analyzed. 
Digoxin concentration measured as total radioactivity was determined  in  serum, urine, 
and stool samples. The amount of radioactivity in various specimens was determined by count- 
ing in a  Tri-Carb liquid scintillation spectrometer (Packard Instrument Co., Inc., Downers 
Grove, Ill.). Internal standards of digoxin-3H were added to each sample and the samples re- 
counted to correct for quenching. 
Serum and urine radioactivity were measured by the addition of 50/~I to 15 ml of a modi- 
fied Bray's scintillation mixture (13), heating at 60°C for 10 min (10), and then counting. Fecal 
radioactivity was determined as follows: each 24-h collection of feces was  added to 50-150 ml 
deionized water and homogenized in a model "45" homogenizer, (The Virtis Co., Inc., Gardiner, 
N.  Y.).  The homogenate was then lyophilized. The dry weight of the homogenate was de- 
termined. A 20-50 mg sample was then combusted (Packard Tri-Carb model 305 tissue oxi- 
dizer, Packard Instrument Co., Inc.) and transferred to 15 ml of a scintillation mixture con- 
taining 300 mg 1,4-bis-2-(4-methyl-5-phenyloxazolyl)-benzene, 5 g 2,5-diphenyloxazole, 100 g 
naphthalene, 45 ml absolute methanol, 135 ml toluene, and 720 ml dioxane. The samples were 
then assayed for radioactivity in the liquid scintillation spectrometer, as described above. 
The radioactivity in the samples analyzed was expressed in mieroeuries on the basis of ob- 
served counting efficiency (which varied from 23 to 31% in various samples), and then calcu- 
lated as nanograms digoxin on the basis of the specific activity of the administered glycoside 
(72 #Ci/mg). It was assumed that metabolic degradation of the digoxin-aH was minimal (18) 
and therefore no correction was made for the presence of radioactive metabolic degradation 
products in the specimens analyzed. 
The serum radioactivity was plotted on a  logarithmic scale (ordinate) against time on a 
linear scale (abscissa) and followed until the curve became monoexponential (19). This final 
linear portion of the curve was used to compute the half time of the slowest component of the 
serum digoxin disappearance curve (20).  It is thought that this slowest component is pre- 
dominantly influenced by metabolism and excretion of digoxin (21). The data was then also 
analyzed by a  digital computer technique for nonlinear regression analysis by which param- 
eters were estimated by a least squares procedure (22). This allowed accurate compartmental 
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Radioiodinated T-globulin and antibody: 131I-7-globulin (5 mCi/kg body weight) and 125I- 
antidigoxin antibody (15  mCi/kg)  were administered in  10 ml  0.15  M  phosphate-buffered 
saline to three groups of animals: one group  of nonimmunized animals received only 131I-  7- 
globulin and l~SI-antidigoxin antibody; the second group of nonimmunized animals received, 
in  addition, 0.25  mg digoxin and 8  ml  of rabbit antidigoxin serum  (digoxin-binding titer 
1:2000); the third group of digoxin-immunized rabbits were given autologous 125 I-antidigoxin 
antibody and 0.25 mg digoxin in addition to 13xI-7-globulin.  The disappearance rates of radio- 
labeled T-globulin and antidigoxin antibody were determined by measuring serum radioac- 
tivity in an Auto-Gamma spectrometer (Packard Instrument Co., Inc.) on specimens obtained 
at 1, 6, and 24 h, and daily thereafter for a  period of 3 wk. Corrections were made for back- 
ground, decay during counting, and channel crossover. This data was also analyzed by com- 
puter as described for digoxin, and the curves divided into exponential functions. These curves 
were all described by two exponentials. The tl/2 of the slower exponential was considered as the 
more important in assessing the metabolism of 7-giobulin and of antibody. 
Immune Complexes.--The  dextran-coated characoal and double antibody methods were 
used to document the presence of hapten-protein complexes in serum. 
The dextran-coated charcoal method (5, 9, 10) was carried out as follows: to each of four 
tubes, 1.0 ml of a 1:20 dilution of the test serum in 0.35% buffered albumin (5) was delivered. 
To two tubes, 0.25 ml of dextran-coated charcoal (2% dextran T-70, 20% charcoal in Tris- 
buffered saline, pH 7.4)  was added and to two control tubes was added 0.25 ml buffered al- 
bumin (5). The contents of the test tubes were mixed and then centrifuged at 2,000 rpm for 60 
rain at 4°C. The supernatant was then poured out into scintillation vials to which 15 ml of 
modified Bray's liquid scintillation counting solution (13) was added, and the vials were then 
counted as described above for serum samples. Protein-binding was expressed as the amount 
of digoxin (radioactivity) present in the supernatant of the tubes to which dextran-eoated char- 
coal had been added, divided by the total amount of digoxin in the test sera, as determined in 
control tubes containing buffered albumin without charcoal. 
The double antibody method (23)  was utilized to determine whether or not the digoxin 
was immunoglobulin bound. Test serum (50/zl of a 1:4 dilution in buffered albumin) was added 
in duplicate to 1.0 ml of sheep anti-rabbit T-globulin (anti-RGG), employed as whole serum 
or as a globulin fraction prepared by the sodium sulfate method (24). The tubes were placed in 
a 37°C water bath for 1 h, refrigerated at 4°C for 5 days, and then centrifuged for 1 h at 4°C 
and 2,000 rpm. The precipitates were washed three times with chilled 0.85% NaC1, digested in 
0.5 ml Soluene (Packard Instrument Co., Inc.), transferred to scintillation vials with the aid of 
two 5 ml portions of Dimilume (Packard Instrument Co., Inc.) and then counted as described 
above for serum samples (in a few early experiments, 1 ml of Soluene was used, followed by 15 
ml of a toinene-Triton X-100 scintillation mixture [5], but significant chemiluminescence was 
encountered, causing delays before accurate counting could be carried out). The supernatant 
solutions were assessed for residual immunoglobulin-bound radioactivity by the addition of 
0.2 ml anti-RGG, followed by the same incubation, washing, and counting procedure described 
above; in no instance was significant radioactivity detected in the second precipitate. Immuno- 
globulin-bound digoxin was calculated as the percent of the serum radioactivity detected in 
the original precipitate. 
Identification of Digoxin.--To  demonstrate that the tritium radioactivity in certain test 
sera reflected the persistence, at least in part, of digoxin-SH,  1.0 ml 25% ethanol was added to 
1.0 ml serum; the solution than was passed over a 2  X  100 cm column of Bio-Gel P-30 (Bin- 
Rad Laboratories, Richmond, Calif.) suspended in 25% ethanol. Fractions containing tritium 
(early protein-containing fractions in the ease of antidigoxin sera, or late protein-free fractions 
in the case of normal control sera) were pooled, lyophilized, and resuspended in 95% ethanol. 
Following centrifugation to remove ethanol-insoluble material (principally protein), the super- 
natant solution was concentrated by evaporation, resuspended in 95% ethanol, and again 
centrifuged to remove precipitated material. After a second evaporation step, 50/zl nonradio- 282  PERSISTENCE OF HAPTEN-ANTIBODY  COMPLEXES 
active digoxin (3 mg/ml in 95% ethanol) was added. A 10/zl sample was removed for count- 
ing, and the remaining 40/~1 was subjected  to thin layer chromatography on Silica Gel G 
(Analtech, Inc., Wilmington, Del.) as previously described (13). Test plates were scraped in 
0.5-cm segments, and the fractions thus obtained were combusted, counted in a scintillation 
spectrometer, and a zonal profile drawn. Results were expressed as percentages of recovered 
radioactivity found in the digoxin peak on the thin layer chromatogram. 
RESULTS 
Disappearance of Serum Digoxin.--In  Fig. 1 a representative computer-fitted 
serum digoxin-SH disappearance  curve observed in one of nine nonimmunized 
rabbits  is  plotted  together  with  a  representative  disappearance  curve  from 
one  of four additional  control  rabbits  immunized  with  BSA.  The serum  tl/2 
in the nonimmunized rabbit illustrated in Fig. 1 was 2.8 days and the dominant 
tl/~  in the rabbit immunized with BSA was 8.6 days (Table II). 
In the nine nonimmunized rabbits  (Table II), the mean 12-h serum digoxin 
concentration was 92  ±  6 ng/ml and the serum tl/2 was 3.4 q- 0.7 days. The 
mean  12-h  serum  digoxin concentration  in  the  four rabbits  immunized  with 
BSA (Table II) was somewhat higher,  126 ng/ml, and the dominant tl/2 some- 
what longer, 9.4 days, than the values observed in nonimmunized animals. 
In Fig. 2, the serum disappearance curve of digoxin-3H in each of five indi- 
vidual digoxin-immunized rabbits is illustrated.  The sera from all five rabbits 
contained  antidigoxin  antibodies  in high titer  (Table  I).  12-h serum  digoxin 
concentrations  were almost  100 times  greater  than  those  observed in control 
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FIO. 1.  Representative  computer-fitted  disappearance curves of serum digoxin-3H in two 
control animals: DS, a nonimmunized rabbit (©); and BSA 37. which had been immunized 
with unconjugated BSA (0). D.  H.  SCHMIDT~ B.  ~¢.  KAUFMAN~ AND  V.  P.  BUTLER~ JR. 
TABLE II 
Serum Concentrations and Serum Disappearance Rates of Digoxin-3H 
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Rabbit no.  12-hr serum  Half-time of exponential  (days)*  Length of 
concentration  1st  2nd  3rd  study 
ng/ml  days 
Nonimmunized 
D-1  94  3.38  10 
D-3  89  4.54  10 
D-4  60  2.64  10 
D-5  94  2.69  10 
D-6  114  3.88  10 
D-7  92  4.11  28 
D-8  71  2.82  16 
D-9  97  3.33  29 
D-10  115  2.98  29 
Mean (±  SD)  92  (±  6)  3.37  (±  0.67)  17 
Immunized with BSA 
BSA-20  118  0.51  9.39  32 
BSA-26  111  0.54  10.09  15 
BSA-33  144  0.53  9.47  34 
BSA-37  131  0.50  8.63  41 
Mean  126  0.52  9.40  31 
Immunized with BSA-Dig 
DC-20  9,600  0.77  8.19  113.7  330 
DC-23  5,390  0.45  6.12  50.5  410 
DC-24  7,800  0.5~  6.4~.  56.9  425 
DC-25  9,500  0.6~  7.5:~  --  21 
DC-26  9,040  0.5~  7.3~  67.5  450 
Mean  8,300  0.56  7.10  72.2  327 
* Serum digoxin-3H disappearance was described by a single exponential (compartment) 
in nonimmunized rabbits,  two  exponentials in rabbits immunized with BSA, and three 
exponentials in rabbits immunized with BSA-Dig. A tx/~ was determined for each exponen- 
tial, although the tl/2 of the final, slowest exponential was considered to be dominant in each 
group of animals. 
:~ Exponential could not be derived from computer analysis; value was obtained graphi- 
cally. 
rabbits and varied between 5,400 and 9,600 ng/ml. In these rabbits the domi- 
nant serum half time of digoxin varied from 51 to 114 days. 
In Fig.  3,  a  representative computer-fitted disappearance curve of  radio- 
active digoxin in a normal nonimmunized  rabbit is plotted as a function of time 
in weeks instead of days and compared with a  representative computer-fitted 
disappearance curve of digoxin-3H in a  digoxin-immunized rabbit. The rapid 
disappearance of digoxin in the nonimmunized animal is in marked contrast 
with the serum digoxin disappearance curve in the rabbit which had been im- 284  PERSISTENCE  OF HAPTEN-ANTIBODY  COMPLEXES 
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FIG.  2.  Disappearance of serum digoxin-*H in five rabbits immunized with BSA-dlgoxin. 
Crosses indicate times of death. 
munized with a  BSA-Dig  conjugate.  In  five digoxin-immunized rabbits,  the 
serum  digoxin  disappearance  curves  were  described  by  three  exponentials 
(compartments). The mean tl/2 of the first exponential was 0.56 days, that of 
the second 7.1 days, and that of the third and dominant exponential was  72 
days, which was 21 times longer than the single tl/2 of 3.4 days observed in the 
nonimmunized rabbits (Table II). The mean 12-h serum digoxin concentration 
in digoxin-immunized rabbits  (Table II)  was  8,300 ng/ml as compared with 
92 ng/ml observed in the control group. At 1 yr, the mean serum digoxin con- 
centration in the digoxin-immunized group had fallen to 85 ng/ml (Fig. 2), a 
value comparable with the 12-h serum digoxin concentration in nonimmunized 
animals (Table II). 
Excretion of Digoxin.--The  per  cent  of  the  administered  dose  of  labeled 
digoxin which was excreted by the rabbits in 10 days is shown in Fig. 4. In nine 
nonimmunized rabbits,  77 % of the total administered dose was excreted in 10 
days. In  the four rabbits immunized with  BSA  in  whom  digoxin-3H  had  a 
slightly longer half-life than in the nonimmunized rabbits  (Fig.  1),  a  total of 
57 % was excreted. In contrast, the five antidigoxin  rabbits excreted a  mean 
total of 8 % of the administered dose, 6 % in the feces and 2 % in the urine. This 
diminished excretion was in keeping with the prolonged serum half-life of the 
hapten. 
Immune  Complexes.--To  determine  whether  the  persistence  of  tritiated 
digoxin in the circulation reflected its presence in complex with antibody in the D.  H.  SCHMIDT,  B.  M.  KAUFMAN,  AND  V.  P.  BUTLER,  JR.  285 
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FIG. 3.  Comparison of computer-fitted serum digoxin-SH disappearance curves in rabbit 
DS, a nonimmunized animal (O), and in a digoxin-immunized rabbit, DC23 (Q). (The values 
used for rabbit D8 are the same as those plotted in days, rather than weeks, in Fig. 1.) 
serum of digoxin-immunized animals, the binding of radioactivity in the sera of 
nonimmunized control rabbits and the rabbits  immunized with BSA-digoxin 
was determined (Table III). In the nonimmunized control rabbits bled at 15 
and 30 rain, a mean of 9 % of the labeled digoxin was protein bound as deter- 
mined by the dextran-coated charcoal method and 2 %  was "y-globulin-bound 
as determined by the double antibody method. In contrast, in the rabbits im- 
munized with BSA-Dig, in sermn obtained between 12 h  and 11 mo after the 
infusion of digoxin,  a  mean of 95 %  of the total serum digoxin was protein- 
bound  as  determined by the  dextran-coated charcoal method and 95 %  was 
bound to immunoglobulin as measured by the double antibody method. 
Identification of Digoxin.--In  serum obtained from four digoxin-immunized 
rabbits 4-9 mo after the administration of digoxin-3H, 66 %  of the recovered 
radioactivity migrated together with digoxin on thin layer chromatography. In 
serum obtained from a  nonimmunized rabbit 30 min after administration of 
digoxin-3H, 89 % of the recovered radioactivity migrated with digoxin on similar 
thin layer chromatographic analysis. 
Serum  Complement.--Sera  from  three  rabbits  immunized  with  BSA-Dig, 286  PERSISTENCE  OF  tIAPTEN-ANTIBODY  COMPLEXES 
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FIo. 4.  Percent of administered digoxin-aH excreted in urine and feces in I0 days in  three 
groups of rabbits: nonimmunized, those immunized with BSA, and those  immunized with 
BSA-digoxin. 
TABLE III 
Binding of Digoxin-SH in Rabbil Sera 
Rabbit no.  Time of bleeding  Serum  digoxin-~H 
Digoxin-aH Bound 
Dextran-coated  Double  antibody 
charcoal method*  methods 
Nonimmunized 
NI-5 
NI-6 
mlml  %  % 
15 min  755  6  1 
30 min  589  6  1 
15 min  526  11  2 
30 rain  357  11  2 
Immunized with BSA-Digoxin 
DC-20  12 h  10j339  97  100 
1 mo  3,072  96  88 
10 mo  698  94  87 
DC-23  72 h  3,913  88  91 
1 mo  1,968  95  97 
9 mo  53  100  87 
DC-24  48 h  5,413  98  99 
2 mo  3,082  92  95 
11 mo  238  100  89 
DC-25  48 h  8,329  100  99 
10 days  4,733  95  98 
DC-26  12 h  9,446  94  99 
1 mo  3,538  89  99 
9 mo  205  92  98 
* Test performed on 1: 20 dilution of serum. 
Test performed on 1:4 dilution of serum. D.  It.  SCI-IMIDT~  B.  M.  KALIFMAN~  AND  V.  P.  BI3"TLER~  JR.  287 
obtained  13-14 mo after giving digoxin, contained 60-100  50%-complement 
units per milliliter, values which were similar to those determined in sera ob- 
tained from normal control rabbits  and to values reported by other investi- 
gators in normal rabbit sera, using a similar method (25). 
Disappearance of ~l-Glotrulin and Digoxin-Specific A ntibodies.--To  determine 
whether the prolongation of half-life of digoxin in  the serum  of digoxin-im- 
munized rabbits was accompanied by a  prolongation of the half-life of anti- 
digoxin  antibody,  the  disappearance  of  ulI-~/-globulin  and  l~5I-antidigoxin 
antibody from the circulation of three groups of rabbits  was  studied.  Com- 
puter-fitted curves from one of the rabbits in each group are shown in Fig. 5, 
and serum disappearance times from all animals studied are listed in Table IV. 
In four nonimmunized rabbits  given only 131I-~,-globulin and 125I-antidigoxin 
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FIO. 5.  Representative  computer-fitted  disappearance  curves  of  serum  125I-antidigoxin 
antibody (O) and pooled l~lI-~t-globulin (O).  (A) Rabbit AB-9,  a  nonimmunized animal,  re- 
ceived antidigoxin antibody and "y-globulin without digoxin.  (B)  Rabbit AB-5,  also  nonim- 
munized,  received 0.25  mg digoxin  together with antidigoxin  antibody and  qf-globulin.  (C) 
Rabbit DC-37, which had been immunized with BSA-digoxin, received 0.25 mg  digoxin  to- 
gether with "y-globulin and autologous antidigoxin  antibody. 288  PERSISTENCE  OF HAPTEN-ANTIBODY  COMPLEXES 
TABLE  IV 
Serum Disappearance Rates of a311-Rabbit y-Globulin and 12 ~l-Antidigoxin Antibody 
Rabbit no.  Injectate 
Half time of exponential* 
Rabbit ~,-globulln  Antidigoxin antibody 
1st  2nd  1st  2nd 
exponential  exponential  exponential  exponential 
days 
AB-2  7-Globulin and anti-  0.50  9.78  0.56  8.52 
AB-6  digoxin antibody  0.51  6.58  0.49  7.09 
AB-9  0.37  4.31  0.40  3.76 
AB-10  0.16  3.81  0.30  3.53 
Mean  0.39  6.12  0.44  5.73 
AB-4  -r-Globulin, antidigoxin  0.47  4.29  0.40  3.93 
AB-5  antibody, and digoxin  0.37  6.30  0.28  4.82 
AB-7  0.38  4.17  0.21  3.65 
AB-8  0.57  4.02  --  -- 
Mean  0.45  4.70  0.30  4.13 
AB-11  v-Globulin, autologous  0.37  3.49  0.41  3.36 
AB-12  antidigoxin antibody,  0.5:~  4.4:~  0.42  3.91 
DC-37  and digoxin  0.52  5.00  0.39  3.68 
Mean  0.46  4.30  0.41  3.65 
* The disappearance of radioactivity for both 131I-~,-globulin and  125I-antidigoxin  anti- 
body was described as a  two-exponential function. The tl/2  of the longer exponential was 
considered to be dominant. 
:~ Exponential could not be obtained from computer analysis; value was obtained graphi- 
cally. 
antibody without digoxin, the serum half times were 6.1 and 5.7 days, respec- 
tively. In four nonimmunized rabbits given 131I-7-globulin  , 12q-antidigoxin  anti- 
body, and 0.25  mg digoxin, the serum half times of "g-globulin and antibody 
were  4.7  and 4.1  days,  respectively. In  three  rabbits  whose sera  contained 
digoxin-specific antibodies given an injection containing 13q-3'-globulin,  0.25 
mg digoxin, and autologous radioiodinated purified antibody, the serum half- 
times of 7-globulin and of antidigoxin antibody were 4.3 and 3.7 days. 
DISCUSSION 
When a foreign serum protein of high molecular weight is injected into the 
circulation of an  animal  whose  serum  contains antibodies  specific  for  that 
protein, the injected protein forms complexes with the specific antibody and is 
removed from the circulation of that animal more rapidly than it is cleared in 
the absence of antibody  (2).  When injected into the  circulation of animals 
whose sera contain hapten-specific antibodies, hapten-protein conjugates are 
rapidly cleared in a similar manner (26). 
In contrast, relatively little is known about the fate of low molecular weight D.  H.  SCHMmT, B.  M.  KAUFMAN,  AND  V.  P.  BUTLER,  JR.  289 
protein antigens or of unconjugated haptens in the circulation in the presence 
of antibody. Berson et al. showed that the biologic half-life of insulin-13~I in the 
circulation of humans with antibodies to insulin was approximately five times 
longer  than  in  the  circulation  of individuals  without  such  antibodies  (27). 
Wheeler,  Kagan,  and  Glick have  made  similar  observations  in  rabbits  im- 
munized against  the nonapeptide hormone oxytocin (28).  Rothenberg et al., 
employing folic acid as a  hapten,  have immunized rabbits with protein-folic 
acid conjugates and have reported that the plasma clearance of 3H-folic  acid 
was altered in immunized animals in comparison with nonimmunized rabbits. 
The plasma concentrations of folic acid were 3.5  times greater at  1 min and 
plasma clearance was threefold slower in the immunized rabbits as compared 
with the control animals (29). 
The current study demonstrates that there is a very striking alteration in the 
clearance of the hapten,  digoxin, from the circulation of animals immunized 
with a digoxin-BSA conjugate in comparison with the clearance of digoxin from 
the circulation of nonimmunized animals  or of animals  immunized with un- 
conjugated BSA.  Following a  single intravenous injection of 0.4 mg digoxin 
per  kilogram  body weight,  the  serum  digoxin concentration  12  h  later was 
8,300 ng/ml in digoxin-immunized animals, in contrast with concentrations of 
92 ng/ml and 126 ng/ml in nonimmunized animals and BSA-immunized ani- 
mals,  respectively. Despite the high serum levels of digoxin, the excretion of 
digoxin was markedly diminished in the digoxin-immunized rabbits in contrast 
with control animals. The serum half-life of digoxin was markedly prolonged in 
the digoxin-immunized group in which the tl/~ was 72 days, in comparison with 
the values of 3.4 days and 9.4 days in the nonimmunized rabbits  and BSA- 
immunized rabbits, respectively. Most striking of all was the observation that 
the digoxin persisted in the circulation of digoxin-immunized animals  for as 
long as 14 mo after a single intravenous injection of the hapten and without 
any subsequent injections of the immunogenic digoxin-protein conjugate. As 
late as 1 yr after this single digoxin injection, the mean serum digoxin concen- 
tration in the digoxin-immunized animals was 85 ng/ml, a  value comparable 
with the mean 12-h value in noninlmunized rabbits. 
Evidence that these alterations in digoxin metabolism in digoxin-immunized 
rabbits are due to the presence of circulating hapten-antibody complexes was 
obtained. The majority of the serum radioactivity in digoxin-immunized ani- 
mals was immunoglobulin bound whereas in nonimmunized rabbits only 2 % 
of the serum radioactivity was so bound. Most of the serum radioactivity was 
indeed intact hapten,  as evidenced by the fact that  the serum radioactivity 
from four rabbits obtained 4-9 mo after the infusion of digoxin contained at 
least 66 % digoxin-3H as determined by thin layer chromatographic analysis. 
On the basis of these observations, we have concluded that hapten-antibody 
complexes may persist  in  the  circulation of immunized  animals  for periods 
greater than 1 yr after a single intravenous injection of hapten. It is presumed 290  PERSISTENCE  OF  HAPTEN-ANTIBODY COMPLEXES 
that the binding of digoxin to  antibody markedly inhibits its renal and fecal 
excretion and its metabolic degradation. Less clear, however, is the basis for 
its prolonged persistence in the serum in complex with rabbit 3,-globulin,  the 
half-life of which has been estimated to be 5-8.6 days (30).  Since complexing 
with hapten may confer some protection to antibody against degradation by 
proteolytic enz)anes in vitro (31, 32), experiments were carried out to determine 
whether digoxin might inhibit the metabolic degradation of antidigoxin anti- 
body in vivo. In these experiments, the half-life of 125I-antidigoxin antibody 
in the presence of digoxin (4.1 days) did not differ significantly from its half- 
life in the absence of digoxin (5.7 days) nor from the half-life of pooled normal 
7-globulin labeled with 181I (5.1 days). Thus, in the current study no evidence 
was obtained in support of the hypothesis that the hapten, digoxin, prolongs 
the half-life of antidigoxin antibody in vivo. Our data seems most consistent 
with the hypothesis that, as digoxin is released from the antibody molecule in 
the normal process  of immunoglobulin catabolism,  the  released  molecule is 
immediately or soon thereafter bound by another preformed or newly formed 
antidigoxin antibody molecule. It is possible,  of course, that digitalis-binding 
sites, which are believed to be on the membranes of all mammalian cells (33), 
may serve as a temporary reservoir for digoxin during the postulated transfer 
from one antibody molecule to another. 
A finding of uncertain significance in this study was the prolongation of the 
mean  serum  disappearance  time  of  digoxin-~H  in  BSA-immunized animals 
(tl/2  =  9.4 days) in comparison with nonimmunized animals (tl/2 =  3.4 days). 
Associated with the slowed disappearance of digoxin-3H from the sera of BSA- 
immunized animals was a  10-day digoxin-3H excretion of 57% of the adminis- 
tered dose,  in  comparison with  77%  digoxin-3H  excretion in nonimmunized 
rabbits.  No digoxin-binding capacity has been detected in the  sera of BSA- 
immunized rabbits  (Table  I)  and  the  basis  for  the  altered  metabolism  of 
digoxin-3H in these animals is not known. It is, however, of interest to note that, 
by computer analysis of the digoxin-~H  disappearance curves in digoxin-im- 
munized rabbits  (Table II),  a  component with a  tl/2 of 7.1  days was noted 
(similar to the dominant exponential, tl/2  =  9.4 days, in the BSA-immunized 
rabbits); it is conceivable that this early component in the digoxin-immunized 
animals is a  reflection of an as yet undefined process which may occur as a 
nonspecific result of the immunization procedure employed. In this connection, 
it is of interest to note that we have previously reported that rabbits which 
have been injected with Freund's complete adjuvant mixture, with or without 
protein  antigens  not  containing  digoxin,  frequently  tolerate  digoxin  doses 
which are usually lethal in noninununized animals (5). 
The  unexpectedly long persistence  of  digoxin-antibody complexes  in  the 
circulation of the rabbits  in this study raises the possibility that drugs and 
other low molecular weight determinants may persist in complex with antibody 
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Such complexes could be of clinical importance in certain instances of delayed 
and prolonged  drug allergies and of some idiosyncratic drug reactions  (34). 
It is well recognized that experimental  animals immunized with protein anti- 
gens exhibit a greater increase in serum T-globulin concentration than can be 
accounted for on the basis of the appearance of antibody capable of precipitating 
with the immunizing antigen (35). In this connection, the present study raises 
the possibility that some or all  of these so-called "nonspecific"  immunologic 
responses to protein antigens may reflect the presence in serum of specific anti- 
bodies, the antigen-binding  sites of which are occupied by low molecular weight 
determinants (perhaps degradation products of the protein antigen)  and which 
therefore are not specifically precipitable  by the corresponding protein antigen 
when conventional  precipitin  techniques  are employed (36). 
Finally, the persistence of antibody-hapten complexes in the circulation sug- 
gests that these complexes may not be deposited in tissues. Since haptens and 
other low molecular weight determinants are capable, by virtue of their ability 
to react with antibody-combining  sites, of inhibiting or reversing the precipita- 
tion of certain antigen-antibody complexes in vitro, it seems reasonable  to 
speculate  that haptens and certain low molecular  weight determinants (e.g., 
enzymatic digests of protein or nucleic acid antigens)  may prevent or reverse 
the formation and tissue deposition of immune complexes caused by the inter- 
action  between  antibodies  and  macromolecular  antigens  in  experimental 
animals and man (36). In this connection,  it is known that,  in rabbits with 
immune  complex  glomerulonephritis  due  to  BSA-anti-BSA  complexes, the 
intravenous administration of sufficient BSA  to produce  a  state of extreme 
antigen excess promotes dissolution  of renal antigen-antibody complexes (37, 
38). However,  the use of a protein antigen may result in increased  antibody 
formation; thus, its beneficial effect may be evanescent  and may be followed 
by a  greater degree  of antigen-antibody complex deposition  than had been 
present initially. In contrast, hapten and low molecular  weight determinant 
groupings  have the advantage of being nonimmunogenic  and, moreover,  the 
unexpectedly long persistence of hapten-antibody complexes in the circulation 
of the animals in the current study suggests  that their postulated effect on 
immune complex deposits may be a very protracted one. 
SUMMARY 
To study the fate of a low molecular weight antigen (hapten) in the circula- 
tion of animals whose sera contain antibodies  specific for that low molecular 
weight antigen, a single injection of digoxim3H (0.4 mg/kg) was administered 
intravenously to 18  rabbits.  Thirteen animals (nine nonimmunized and four 
immunized with bovine serum albumin) served as control animals. In five rab- 
bits which had been immunized with a digoxin-bovine serum albumin conjugate 
and whose sera  contained  digoxin-specific antibodies,  the mean  12-h serum 
digoxin  concentration was  8,300 ng/ml  (control:  92  ng/ml)  and  the  mean 292  PERSISTENCE  OF  ttAPTEN-ANTIBODY  COMPLEXES 
serum  concentration  12  mo  after  the  single  injection  of digoxin-~H  was  85 
ng/ml.  In digoxin-immunized  rabbits,  less  than  10%  of the  digoxin-3H was 
excreted in the first 10 days (control: 77 % recovered in urine and feces) and the 
mean biological half-life of digoxin,  as calculated from serum digoxin-3H dis- 
appearance  curves,  was  72  days  (control:  3.4  days).  In  sera  of digoxin-im- 
munized rabbits, more than 90%  of the circulating digoxin-3H was immuno- 
globulin  bound,  as  determined  by  the  double-antibody  and  dextran-coated 
charcoal methods. 
The serum disappearance rate of 12SI-antidigoxin  antibodies was similar in 
nonimmunized and in  immunized animals and in  the presence or absence of 
digoxin. 
It is concluded that the biological half-life of a hapten may be markedly pro- 
longed  when  the  hapten  is  bound  to  specific  antibody.  The  persistence  of 
antibody-hapten complexes in  the  circulation  suggests  that  these  complexes 
may not be deposited in tissues and raises the possibility that low molecular 
weight determinants may be capable of preventing or reversing the deposition 
of immune complexes, containing  macromolecular antigens,  in  the  tissues  of 
experimental animals and man. 
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